13451-78-0

Basic information

• Product Name: 5-FLUOROBENZO[D]OXAZOLE-2-THIOL
• Synonyms: 5-FLUOROBENZO[D]OXAZOLE-2-THIOL;5-Fluoro-2(3H)-benzoxazolethiene;5-Fluorobenzoxazole-2-thiol;2-Mercapto-5-fluorobenzoxazole;5-Fluorobenzoxazole-2-thiol 97%
• CAS NO: 13451-78-0
• Molecular Formula: C₇H₄FNOS
• Molecular Weight: 169.18
• Mol File: 13451-78-0.mol
• Article Data: 25

Chemical Properties

• Melting Point: 238-240℃
• Boiling Point: 238.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.10±0.20(Predicted)
• Sensitive: Moisture & Light Sensitive
• CAS DataBase Reference: 5-FLUOROBENZO[D]OXAZOLE-2-THIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FLUOROBENZO[D]OXAZOLE-2-THIOL(13451-78-0)
• EPA Substance Registry System: 5-FLUOROBENZO[D]OXAZOLE-2-THIOL(13451-78-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39-24/25
• WGK Germany: 3
• Hazardous Substances Data: 13451-78-0(Hazardous Substances Data)

Usage

General Description

5-FLUOROBENZO[D]OXAZOLE-2-THIOL is a chemical compound with the molecular formula C7H4FNOS. It is a heterocyclic organic compound containing a benzoxazole ring with a fluorine atom and a thiol group attached at the 2-position. This chemical is commonly used in pharmaceutical research and drug development due to its potential therapeutic properties. Its unique structure and functional groups make it a valuable intermediate for the synthesis of various biologically active compounds. In particular, 5-FLUOROBENZO[D]OXAZOLE-2-THIOL has shown potential as a potential lead compound for the development of new drugs targeting certain diseases. Therefore, it is of interest to researchers in the fields of medicinal chemistry and drug discovery.

Upstream product

• 399-97-3 2-amino-4-fluorophenol 
• 128-04-1 sodium dimethyldithiocarbamate 
• 137-26-8 Thiram 
• 35832-93-0 ethoxy(potassiosulfanyl)methanethione 
• 394-33-2 2-nitro-4-fluorophenol 
• 140-89-6 potassium ethyl xanthogenate 
• 75-15-0 carbon disulfide 

Downstream Products

• 135533-78-7 2-chloro-5-fluorobenzo[d]oxazole 
• 1428336-14-4 6-bromo-N-(2-morpholino-5-(piperidin-1-yl)benzo[d]oxazol-6-yl)picolinamide 
• 1428336-13-3 C₁₈H₁₉N₃O₃ 
• 1428336-12-2 5-(benzyloxy)-2-morpholino-6-nitrobenzo[d]oxazole 
• 1428335-37-8 C₂₇H₂₄N₆O₄ 
• 1428335-34-5 C₂₉H₂₆N₆O₄ 
• 1374820-10-6 C₁₇H₁₆Cl₂FN₃O 

Relevant articles and documents

A new series of benzoxazole-based SIRT1 modulators for targeted therapy of non-small-cell lung cancer

In an attempt to identify potential anticancer agents for non-small-cell lung cancer (NSCLC) targeting sirtuin 1 (SIRT1), the synthesis of a new series of benzoxazoles (3a – i) was carried out through a facile and versatile synthetic route. The compounds were evaluated for their cytotoxic effects on A549 human lung adenocarcinoma and NIH/3T3 mouse embryonic fibroblast cells using the MTT assay. 2-[(5-Nitro-1H-benzimidazol-2-yl)thio]-N-(2-methylbenzoxazol-5-yl)acetamide (3e) and 2-[(5-chloro-1H-benzimidazol-2-yl)thio]-N-(2-methylbenzoxazol-5-yl)acetamide (3g) were the most potent and selective anticancer agents in this series against the A549 cell line, with IC50 values of 46.66 ± 11.54 and 55.00 ± 5.00 μM, respectively. The flow cytometry-based apoptosis detection assay was performed to determine their effects on apoptosis in A549 cells. Both compounds induced apoptosis in a dose-dependent manner. The effects of compounds 3e and 3g on SIRT1 activity were determined. On the basis of in vitro studies, it was observed that compound 3g caused a significant decrease in SIRT1 levels in a dose-dependent manner, whereas compound 3e increased the SIRT1 levels. According to molecular docking studies, the substantial alteration in the type of action could be attributed to the difference between the interactions of compounds 3e and 3g with the same residues in the active site of SIRT1 (PDB code: 4IG9). On the basis of in silico ADME (absorption, distribution, metabolism, and excretion) studies, these compounds are predicted to possess favorable ADME profiles. According to the in vitro and in silico studies, compounds 3e and 3g, small-molecule SIRT1 modulators, were identified as potential orally bioavailable anticancer agents for the targeted therapy of NSCLC.

AlCl3-Promoted Synthesis of 2-Mercapto Benzoheterocycles by Using Sodium Dimethyldithiocarbamate as Thiocarbonyl Surrogate

A simple, expeditious and high-efficiency synthetic method for the AlCl3-mediated one-pot preparation of 2-mercapto benzoheterocycles (2-mercapto benzothiazoles, benzoxazoles and benzimidazoles) is described. By the treatment of a series of S, O and N heteroatoms containing bifunctional molecules with sodium dimethyldithiocarbamate in AlCl3, the desired benzoheterocycles are obtained smoothly. The protocol can also be applied on the synthesis of a series of thiazolidine-2-thiones, imidazolidine-2-thiones. This novel synthetic approach has advantages such as ligand-free, high efficiency, short reaction time, readily available starting materials and simple experimental procedures.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.